

Appendix VI

EXTRAORDINARY INFORMATION DISCLOSURE

(Issued with the Decision No. 21/QĐ-SGDVN on December 21, 2021 of the CEO of Vietnam Exchange on the Information Disclosure Regulation of Vietnam Exchange)

**AGIMEXPHARM PHARMACEUTICAL
JOINT STOCK COMPANY**

**THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness**

No.: 05/ CBTT-AGP

Long Xuyen City, February 13, 2025

EXTRAORDINARY INFORMATION DISCLOSURE

To: Hanoi Stock Exchange

1. Name of organization: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
- Stock code: AGP
- Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province
- Tel: 02963.856964
- E-mail: agp@agimexpharm.com
2. Contents of disclosure: Invitation Letter and Documents of the 2025 Annual General Meeting of Shareholders
3. This information was published on the company's website on February 13, 2025, as in the link <https://agimexpharm.com/shareholder/>

We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.

Attached documents:

- Invitation Letter
- Documents of the 2025 Annual General Meeting of Shareholders

**Legal representative
General Director**



Phar. Nguyen Van Kha

An Giang, February 14, 2025

INVITATION LETTER

THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS

To: Shareholders of Agimexpharm Pharmaceutical Joint Stock Company

The Board of Directors of Agimexpharm Pharmaceutical Joint Stock Company cordially invites our valued shareholders to attend the 2025 Annual General Meeting of Shareholders.

1. Time: 8:00 AM on March 8, 2025 (Saturday)

(Document collection starts at 7:30 AM)

2. Venue: Hoa Binh 1 Restaurant

130 Tran Hung Dao, My Binh Ward, Long Xuyen City, An Giang Province

3. Agenda: Discuss and approve contents of the 2024 fiscal year (*see attached agenda*).

4. Participants: Shareholders of Agimexpharm as of February 10, 2025.

In the event a shareholder cannot attend, they may authorize another shareholder or a representative (using the attached Letter of Authorization) to attend on their behalf.

Please confirm your attendance or provide authorization (using the attached form) and send it to Agimexpharm **before 4:00 PM on March 4, 2025** at the following address:

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: 27 Nguyen Thai Hoc, My Binh Ward, Long Xuyen City, An Giang Province

Phone: 0296 3856960 – (Ms. Nguyen Thi An)

Documents for the Meeting, including the Letter of Authorization, are posted and updated by the Company on the website: <https://agimexpharm.com/shareholder/> from February 14, 2025, and printed copies will be provided to shareholders attending the Meeting.

Sincerely.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**



PHAR. PHAM THI BICH THUY



THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

LETTER OF AUTHORIZATION

To attend the 2025 Annual General Meeting of Shareholders
Agimexpharm Pharmaceutical Joint Stock Company

Full name: Shareholder code:

ID/ Passport/ Business Registration Certificate No.: Issued on:

at:

Permanent Address:

Currently holding shares of Agimexpharm Pharmaceutical JSC.

In words:

Hereby authorize Mr./Ms.:

ID/Passport No.: Issued on:

at:

Address:

Or a Delegate who is a Member of the Board of Directors:

No.	Full name	Position	Authorized representative (*)
1	Ms. Pham Thi Bich Thuy	Chairwoman of the Board of Directors - Deputy General Director	
2	Mr. Nguyen Van Kha	General Director - Vice Chairman of the Board of Directors	
3	Ms. Tran Thi Dao	Member of the Board of Directors	
4	Mr. Nguyen Quoc Dinh	Member of the Board of Directors	
5	Mr. Pham Uyen Nguyen	Member of the Board of Directors	
6	Mr. Huynh Hoang Ha	Member of the Board of Directors - Deputy General Director	

To represent me at the 2025 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint Stock Company on March 8, 2025, and to act on my behalf in exercising all rights and obligations at the Meeting in accordance with the number of shares authorized.

I assume full responsibility for this authorization and commit to making no complaints in the future.

.....,, 2025

The Authorized Person
(Signature and Full Name)

The Authorizing Person
(Signature and Full Name)

(*) If authorizing a Delegate, please mark "x" in the column corresponding to the name of the Delegate.



**AGIMEXPHARM PHARMACEUTICAL
JOINT STOCK COMPANY**
No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen
City, An Giang Province
Tel: 0296 3856960 | Fax: 0296 3857301
Website: www.agimexpharm.com

DOCUMENTS

THE ANNUAL GENERAL MEETING OF SHAREHOLDERS

YEAR 2025

(DRAFT)

March 8, 2025



DRAFT

AGENDA

THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS

An Giang Province, March 8, 2025

Timeline	Content
7h30' - 8h30'	I. PROCEDURES
	1. Shareholders complete procedures to receive documents.
	2. Statement of purpose and introduction of participants.
	3. Report on verification of shareholder eligibility to attend the meeting.
	4. Introduction and voting on: - Working regulations; - Meeting agenda; - Presidium; - Secretariat; - Vote Checking Committee.
8h30' - 10h30'	II. MEETING CONTENTS
	1. The 2024 Board of Directors' activity report and assessment - Plans and targets for 2025.
	2. The 2024 Board of Management's business operations report and plans for 2025.
	3. The 2024 Audited Financial Statements.
	4. The 2024 Board of Supervisors' report.
	5. Proposal for selecting an auditing firm for the 2025 financial statements.
	6. Proposal for the 2024 profit distribution and dividend payout.
	7. Proposal for salary and bonus for the Board of Directors and the Board of Supervisors.
	8. Proposal on the plan for issuing shares to pay 2024 dividends.
	9. Proposal on the plan for issuing shares under the Employee Stock Ownership Program (ESOP)
	10. Proposal on amendments to the Company's Charter
	Discussion & Voting.
10h30'- 12h00'	III. CONCLUSION
	Approval of the Draft Resolution of the 2025 Annual General Meeting of Shareholders
	Closing remarks

MEETING ORGANIZING COMMITTEE



DRAFT

WORKING REGULATIONS

AT THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS An Giang Province, March 8, 2025

- Pursuant to the Enterprises Law No. 59/2020/QH14 on June 17, 2020, effective from January 1, 2021;
- Pursuant to the Charter of Organization and Operation of Agimexpharm Pharmaceutical Joint Stock Company;

To ensure the progress of the working schedule in accordance with the meeting agenda, the Organizing Committee respectfully presents the Meeting with the following Working Regulations:

A. Tasks of the General Meeting

Voting on the meeting contents:

1. The 2024 Board of Directors' activity report and assessment - Plans and targets for 2025.
2. The 2024 Board of Management's business operations report and plans for 2025.
3. The 2024 Audited Financial Statements.
4. The 2024 Board of Supervisors' report.
5. Proposal for selecting an auditing firm for the 2025 financial statements.
6. Proposal for the 2024 profit distribution and dividend payout.
7. Proposal for salary and bonus for the Board of Directors and the Board of Supervisors.
8. Proposal on the plan for issuing shares to pay 2024 dividends.
9. Proposal on the plan for issuing shares under the Employee Stock Ownership Program (ESOP)
10. Proposal on amendments to the Company's Charter

B. Regulations of the General Meeting

The Annual General Meeting of Shareholders shall be conducted under the direction of the Presidium. The responsibility of the Presidium is to ensure that the Meeting is conducted in accordance with the law and in line with the company's charter.

I. Voting on the meeting contents:

1. Principles:

All issues must be approved as stipulated and shall be passed by collecting the opinions of the shareholders. Each shareholder or their authorized representative will be provided with a voting slip, indicating the number of shares entitled to vote and bearing the company's seal.

Shareholders may receive more than one voting slip if they hold additional valid authorizations, and the Organizing Committee has not yet consolidated the voting slips into one.

2. Method of direct voting:

Shareholders or authorized representatives vote at the General Meeting of Shareholders by raising their voting slips towards the Presidium to express the following opinions:

- "Approve" the content presented to the General Meeting of Shareholders;

- "Disapprove" the content presented to the General Meeting of Shareholders;
- "No opinion" on the content presented to the General Meeting of Shareholders.

The Vote Checking Committee will record the number of votes marked as "Approve", "Disapprove", or "No opinion" to announce the voting results of the meeting.

II. Discussion at the General Meeting:

At the General Meeting, after hearing the reports and proposals from the Board of Directors and the Board of Supervisors, shareholders or their authorized representatives have the right to discuss and express their opinions that adhere to the following regulations:

- Obtain approval from the Presidium.
- State name and the number of shares owned. Remarks must be to the point and relevant to the agenda of the General Meeting.

III. The Presidium:

The list of the Presidium members is approved by the General Meeting through voting.

Responsibilities of the Presidium:

- Conduct the General Meeting in accordance with the approved agenda and working regulations. The Presidium operates on the principle of collective decision-making and decides by majority vote.
- Guide the General Meeting in discussing and voting on agenda items and related matters throughout the Meeting.
- Resolve any issues that arise during the Meeting.

IV. The Secretariat:

The list of the Secretariat members is approved by the General Meeting through voting.

Responsibilities of the Secretariat:

- Thoroughly record all opinions at the Meeting and compile the reports from the Presidium.
- Draft and finalize the resolutions of the Meeting.
- Draft the minutes of the meeting.

V. The Vote Checking Committee:

The list of the Vote Checking Committee members is approved by the General Meeting through voting.

Responsibilities of the Vote Checking Committee: Check the number of votes marked as "Approve", "Disapprove", or "No opinion" for each issue and report the results immediately to the Meeting Secretary.

This working regulation is presented to the General Meeting of Shareholders and is approved upon receiving the consent of shareholders representing at least 65% of the total voting shares present at the Meeting.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**

PHAR. PHAM THI BICH THUY



DRAFT

An Giang, February 14, 2025

THE BOARD OF DIRECTORS' ACTIVITY REPORT, EVALUATION OF THE COMPANY'S PERFORMANCE IN 2024 PLAN FOR 2025

To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC.

The Board of Directors ("BOD") of Agimexpharm Pharmaceutical Joint Stock Company respectfully presents to the Annual General Meeting of Shareholders ("GMS") the 2024 performance of the BOD and objectives for 2025, with the following key points:

I. ACTIVITIES OF THE BOARD OF DIRECTORS IN 2024

1. Activities of members of the Board of Directors

All members of the Board of Directors (BOD) exhibited a high level of responsibility, fully participating in meetings and effectively performing their functions of directing, managing, and supervising as required. The BOD reached strong consensus when approving resolutions and meeting minutes to promptly resolve challenges and obstacles arising in business operations. During meetings, the BOD forecasted the economic, political, and social situation, analyzed challenges, opportunities, and advantages, and formulated strategic directions for the company's development.

The BOD worked within its functions, duties and authority in compliance with the Enterprises Law, the company's charter and applicable laws. The BOD closely supervised the Board of Management's implementation of resolutions of the GMS and the BOD regarding key company matters.

The information disclosure policy complies with the regulations issued by the BOD according to the principles: Information is transparent, complete, accurate, standard and published on time.

Transactions between the company and its related parties, or between the company and major shareholders, insiders, and individuals related to insiders, were carried out in compliance with regulations (refer to section 2, part VII of the 2024 corporate governance report, which has been disclosed according to regulations).

Transactions between the Company and its affiliated persons or between the Company and its major shareholders, internal persons and affiliated persons (refer to section 2, part VII of the 2024 Report on corporate governance, which has been disclosed according to regulations).

2. Leadership and Supervision activities of the Board of Directors

In accordance with the Company's Charter and Corporate Governance Regulations, the BOD supervised and monitored the activities of the Board of Management in managing business operations and implementing the resolutions of the GMS and the BOD as follows:

Supervision methods:

- Receiving reports and directly questioning the Board of Management during regular BOD meetings.
- Monitoring the fulfillment of key targets committed by the Board of Management in accordance with the resolutions of the GMS and the BOD.
- Regular discussions among members to reach consensus on solutions regarding investment, finance, business operations, project management and procedures. Overseeing and directing the company's investment projects to ensure effective implementation.



Ongoing supervision allows timely decision-making and strategic direction to resolve difficulties and inadequacies in business operations.

- Risk management: Assessing and governing potential risks, including financial, human resources, legal, market and corporate governance risks.

Supervision results:

- The Board of Management and management team have implemented the resolutions and decisions of the GMS and the BOD.
- Throughout operations, the General Director and members of the Board of Management have complied with the regulations of the Company’s Charter and Internal Governance Regulations.
- The General Director has fulfilled the role and responsibilities of a leader, directing and guiding critical company matters while efficiently coordinating the Board of Management’s activities.
- Especially in 2024, despite a complex operating environment, the General Director managed production and business activities flexibly, proposed many timely solutions, adapted to the fluctuating business environment and completed the task of bringing practical value to shareholders.

***Conclusion:** The BOD considers 2024 a successful year for the company, reinforcing faith among shareholders, partners, and the entire Agimexpharm team.*

II. THE COMPANY’S PERFORMANCE EVALUATION IN 2024

1. Performance evaluation

2024 continues to be a volatile year for the global economy. The Vietnamese pharmaceutical industry faced numerous challenges and difficulties, including supply chain disruptions, rising production costs, intense competition and exchange rate pressures....

Faced with that common context, with the efforts and initiative of the Board of Directors and staff, Agimexpharm has implemented many solutions, taken advantage of opportunities, and overcome challenges to complete the targets set by the GMS.

The company strictly complied with the policies and regulations of the State, actively contributed to environmental protection, and fulfilled its social responsibilities.

Under the strategic direction of the BOD and in response to market difficulties, the Board of Management took decisive actions, proposed many flexible strategies, and implemented specific and creative solutions to complete the 2024 production and business plan.

Assessment of the implementation of the GMS’ Resolutions:

CONTENT	IMPLEMENTATION RESULTS
1. The 2024 production and business targets	
Total revenue	VND 799.15 billion
Net revenue	VND 793.26 billion
Profit before tax	VND 60.48 billion
Profit after tax	VND 48.89 billion
2. Selection of independent auditing firm for the 2024 fiscal year	
Authorize the BOD to select 1 of 5 independent auditing firms	Choose A&C Auditing and Consulting Co., Ltd.
3. Profit distribution and dividend payment for 2023	
Dividend payment in shares at 12% of charter capital	The company issued 2,479,488 shares for the 2023 dividend

Bonus for the BOD and the Board of Supervisors for exceeding the profit plan by 1.27% of Profit After Tax	Bonus for the BOD and Board of Supervisors: VND 551,745,246
Allocation to the reward and welfare fund: 6.88% of Profit After Tax	Reward and welfare fund for 2023: VND 2,999,226,098
4. Addition of new business line	Added new business line: Warehousing and storage of goods
5. 2024 Salary and Bonus for the BOD, the Board of Supervisors, and the Board of Management	<i>Refer to item 1a, Section 1, part VII of the Notes to the Financial Statements – The Audited 2024 Financial Statements, which has been disclosed in accordance with regulations</i>

2. Key achievements

Despite capital difficulties due to the investment in the Betalactam Factory, 2024 revenue increased by 9%, and profit increased by 12% compared to the same period last year.

Product quality remains the core value, so the company consistently emphasizes quality management to ensure consumer health and high treatment efficacy.

The 2024 production output: 1.3 billion units, increased by 14% compared to 2023.

Research and development and product registration are invested: In 2024, the Department of Drug Administration granted 54 new registration numbers and 269 renewal numbers.

The Betalactam Factory project was completed with an area of 7,776 m². In early December 2024, the Department of Drug Administration confirmed its GMP compliance.

In 2024, Agimexpharm achieved several achievements: “Vietnamese Drug Star Award – 2nd Edition”, Top 10 ASEAN Strong Brands, Top 100 Vietnam's National Brand – Vietnam Gold Star Award 2024, Vietnam High Quality Goods, Outstanding Enterprise for Employees, and Cultural Enterprise.

The company developed policies for employee benefits, salary, bonus, and training programs to enhance professional skills and ensuring long-term employee loyalty.

As a responsible manufacturer, Agimexpharm focuses on investing in health and safety standards for employees, minimizing environmental impact, and meeting waste treatment standards. The company also increased green coverage at operational sites, engaged in traditional community activities, and contributed to charity funds, scholarships and local government initiatives...

III. PLAN FOR 2025

1. Identifying Opportunities, Challenges, and Risks

The global economic and political situation in 2025 is expected to have a significant impact on the growth of pharmaceutical companies:

- U.S. Tariff Policies: Potential increases in import tariffs could affect the supply chain for pharmaceutical raw materials
- Political conflicts: These could lead to higher energy costs and put pressure on global economic stability, impacting production and distribution activities for pharmaceutical companies.
- Global economic growth: According to United Nations forecasts, global economic growth is expected to remain at 2.8% in 2025. Slower growth could affect consumer demand, including spending on pharmaceuticals

Based on the analysis above, Agimexpharm is facing numerous advantages, challenges, and growth opportunities:

- Regulatory adjustments and additions in the Pharmaceutical Law create a clear legal framework that supports the sustainable development of the company

- Response speed and adaptability are the most influential factors in the company's business results, especially in periods of significant volatility.
- R&D: Agimexpharm has a diverse product portfolio and the ability to effectively leverage its products.
- Technological innovation and process improvement: The management team is dynamic, willing to innovate and act.
- Financial strength: The company's capital is still insufficient to meet its working capital needs and medium-to-long-term investment requirements.
- Human resource quality: There is a shortage of skilled labor to elevate quality and prepare for future leadership succession.
- Sales system and distribution network have not yet been professionally invested in.

2. Target and Plan of the Board of Directors

2.1. Business Plan for 2025

Target	Actual 2024	Plan for 2025	Growth rate (%)
Net Revenue (VND billion)	793.3	868	9.4%
Profit Before Tax (VND billion)	60.5	68	12.4%
Profit Margin (Profit Before Tax/Revenue) (%)	7.6%	7.8%	

2.2. Corporate Governance Objectives

The Vietnamese pharmaceutical industry in 2025 presents numerous growth opportunities but also faces significant challenges. Leveraging advantages and opportunities while overcoming difficulties will be key to Agimexpharm's sustainable development in the future. The BOD has set the following main objectives:

- Ensure responsible governance and compliance with legal regulations, the Company's Charter and the BODs' operational regulations.
- Coordinate with the Board of Supervisors to fully understand the company's operations and provide valuable advice and recommendations to support the Board of Management.
- Strengthen supervise, evaluation and feedback on the Board of Management's activities regarding investments, finance, business operations, production, quality risk management, human resources, project management, etc. Solutions need to be developed to increase the company's capital.
- Organize BOD meetings to promptly address issues with the Board of Management, overcoming obstacles and creating favorable conditions for all company activities.
- Coordinate with the Board of Management in relationships with shareholders, investors, partners, employees and other stakeholders.

Above is the Board of Directors' Activity Report, Evaluation of the Company's Performance in 2024 and outlining plan for 2025. On behalf of the Board of Directors, we would like to sincerely thank our shareholders, investors, partners, customers, and all employees for their trust and support during the past period and in the future.

Sincerely.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**

PHAR. PHAM THI BICH THUY

DRAFT

An Giang, February 14, 2025



REPORT OF THE BOARD OF MANAGEMENT ON BUSINESS OPERATIONS IN 2024 AND PLAN FOR 2025

The year 2024 continues to mark an important milestone in Agimexpharm's journey towards sustainable growth and continuous advancement. Under the leadership of the Board of Directors and the Board of Management, along with the support of shareholders and the efforts of all employees, the Company has overcome numerous challenges to maintain stable growth and fulfill the responsibilities entrusted by our esteemed shareholders. The key achievements are as follows:

1. Revenue and Profit

- Revenue: VND 793.3 billion, rising by 9.4% compared to 2023, exceeding the target by 3%.
- Profit before tax: VND 60.5 billion, rising by 11.6%, exceeding the target by 4.3%.
- Profit after tax: VND 48.9 billion, rising by 12.1%, exceeding the target by 4.7%.

Unit: Million VND

Indicator/Year	2020	2021	2022	2023	2024	5-Year Average
Revenue	494,978	521,798	687,047	725,130	793,261	11.6%
Profit before tax	36,298	41,378	53,239	54,196	60,481	11.6%
Profit after tax	28,870	33,226	42,910	43,613	48,890	11.9%

The results above reflect the sustainable effectiveness of the company's business strategy, market expansion, and strict adherence to financial regulations.

2. Production and Distribution

- **Production:** The production output for the past year is as follows:

Unit: Million VND

Product	ĐVT	2020	2021	2022	2023	2024	+/-% 2023
Powder Sachets	Sachet	19.38	21.35	34.38	33.29	32.23	-3.2%
Suspension Sachets	Sachet	0.35	11.81	17.52	16.21	14.98	-7.6%
Capsules	Capsule	115.83	132.95	166.40	198.92	235.32	18.3%
Tablets	Tablet	601.16	690.07	827.72	923.78	1,051.48	13.8%
Liquid Medicine	Sachet/ Vial/ Bottle	14.32	2.14	4.13	3.70	6.37	72.2%
Granules	Bottle	0.51	0.35	0.50	0.49	0.41	-16.3%
Creams	Tube	0.84	0.73	0.74	1.05	1.30	23.8%
Total		752.39	859.42	1,051.39	1,177.44	1,342.09	14.0%

Agimexpharm has optimized production capacity at 4 factories, including: My Thoi Capsule-Granule-Powder; My Thoi Cream-Ointment-Liquid; Binh Hoa Non-Betalactam Capsule-Granule-Powder; Herbal medicine and Health supplement. As a result, the total production output reached 1.34 billion units, a 14% increase compared to the year 2023, along with the development of 30 new products and new packaging formats. This achievement was made possible by:

- The application of automation and management software has helped improve productivity and minimize errors.

- The testing laboratory compliant with GLP.ISO 13485 standards, equipped with advanced technology and a highly skilled team, completed **21,000 samples** during the year, ensuring product quality complies with the strict pharmaceutical industry regulations.
- Strengthened quality assurance (QA): regular inspections and audits to ensure products are manufactured according to quality procedures.

• **Distribution:**

Agimexpharm has a **diverse product portfolio** with **597 finished product codes** currently supplied to customers, which strengthens the company’s competitiveness in the challenging pharmaceutical environment. The market share and growth rates of the product groups are as follows:

Group	% of 2024 Revenue	% of 2023 Revenue
Anti-inflammatory agents, Antibiotics, Antivirals, Antihistamines	32.4%	32.7%
Cardiovascular system, Antidiabetic	21.2%	21.2%
Alimentary tract and Metabolism	14.3%	15.4%
Health supplements-Cosmetics-Medical devices; Vitamins-Minerals, Herbal medicines	9.5%	10.3%
Other groups (Analgesics, Skeletal Muscle Relaxants, Nervous system, Genitourinary system...)	22.6%	20.4%

The ETC channel played a key role and grew compared to the year 2023, accounting for **51%** of total revenue. The OTC channel declined at branch levels due to intense competition between traditional pharmacies and new chain systems. Meanwhile, the manufacturing facilities attracted more contract manufacturing partners, contributing to revenue and serving as an effective branding tool, reinforcing the company’s reputation and product quality.

Nationwide distribution: **An Giang Province** played a key role in maintaining stability (accounting for 34% of revenue, increasing by 7%). The key market of **Ho Chi Minh City and neighboring provinces** (accounting for 41% of revenue, increasing by 13%), while **Da Nang and the Central region** (accounting for 22%, increasing by 11%). Revenue from the **Northern region** serves as a foundation for future growth.

In addition to the domestic market, Agimexpharm is actively expanding into international markets. In 2024, the company made significant progress by maintaining exports to Cambodia and Myanmar, while also targeting new markets such as South Korea, Yemen, Somalia and Afghanistan.

To ensure the timely and accurate distribution of its products, Agimexpharm’s logistics and warehousing system operates with **31 personnel**, managing **5 warehouses** with a total area of **7,589m²**. The fleet includes **7 trucks** (ranging from 500 kg to 8 tons), which transported **9,694 tons** of raw materials and packaging and **4,150 tons** of finished products in 2024.

3. Innovation and Sustainable Development Investment

In 2024, new asset investments totaled **VND 195 billion**, allocated to the construction of the Betalactam Plant, maintenance and upgrades of existing assets, infrastructure expansion, the addition of 3 solar energy systems, production machinery, and testing equipment. This represents the highest investment level to date, raising the total value of fixed assets to **VND 562 billion, increasing by 53%**. Additionally, ongoing projects and equipment under construction amount to **VND 47 billion**, including the expanded Herbal Medicine Plant, the Liquid Pharmaceutical Plant (for infusions, injections, and eye drops), and the Canteen and Parking facility for the Binh Hoa Industrial Park manufacturing complex.

Continuous investment is a crucial step, reflecting the strategic vision of the Board of Management to be ready to meet the growing demands of the market and lay the foundation for future growth. The Betalactam Antibiotic Plant with an area of **7,776m²**, was completed after 14 months of construction and successfully passed the evaluation process. It is now capable of developing new product lines.

The R&D team has completed **750 registration files**, including product registrations, renewals, and various procedures, resulting in the issuance of **717 marketing authorizations**. They also conducted **410 research samples**, of which **111 samples** met the required quality standards.

In line with energy-saving initiatives and the green production strategy, a new solar energy system was installed, adding **1,317 kW** in 2024. As a result, the company's total capacity reached **2,465 kW**, reducing electricity costs by **VND 7 billion** per year, cutting carbon emissions, and contributing to environmental protection.

4. People and Social responsibility

With a long-term vision, Agimexpharm has made sustainable investments in human resources, simultaneously fulfilling its social responsibilities and laying a solid foundation for long-term growth.

By the end of 2024, the company had nearly **490 employees** working in a well-structured environment with comprehensive welfare policies. Employees are empowered to develop their capabilities, provided with career advancement opportunities, and receive competitive salaries and benefits. The total salary expenditure for the year 2024 reached **VND 52.5 billion, rising by 7%**. The recognition and rewards for outstanding individuals and teams serve as motivation for continued growth.

For shareholders, Agimexpharm ensures the protection of interests and capital preservation by maintaining stable dividends and sustainable stock value. In 2024, the company distributed **dividends at 12%**. As of December 31, 2024, the stock price was **VND 38,900 per share**, reflecting stability and market confidence in the company's development strategy.

In fulfilling its responsibilities to the State, Agimexpharm remains highly aware of its obligations beyond business growth. In 2024, the company fully complied with tax obligations, contributing **VND 14 billion** to the national budget.

5. Awards and Certifications

Top 10 Asean Strong Brand

Top 100 Vietnam's National Brand – Vietnam Gold Star Award 2024

Vietnam High Quality Goods

Vietnam Pharmaceutical Star Award

2023-2024 Cultural Enterprise

Outstanding Enterprise for Employees

GMP, GSP, GLP, GDP Certifications; ISO 13485:2016

6. Challenges and Opportunities

The rising cost of raw materials remains a significant challenge, accounting for a substantial portion of product costs and being influenced by various factors such as transportation expenses, exchange rates, supply chain disruptions, and stringent regulations. Over the year, the company spent **VND 480 billion** on raw materials and packaging, including direct imports of **30 types** of materials with a total value of **VND 84 billion** (increased 1.75 times). Optimizing raw material costs, combined with efforts to diversify supply sources, helps Agimexpharm improve its competitiveness and proactively respond to future challenges related to raw material costs.

Capital is another significant challenge when expanding scale and investing in strategic projects. From the shareholders' contributed capital of **VND 231 billion**, assets have now grown to **VND 1,094 billion**. The equity turnover ratio reached **2.1 times**, and the return on equity (ROE) was **13%**, affirming profitability and long-term growth potential. As a result, the company has opportunities to access funding from banks for buying raw materials and implementing investment projects.

Effective cash flow management ensures liquidity. Cash flow from operating activities reached **VND 60.8 billion**, an increase compared to 2023, thanks to enhanced cost control, sales, and debt



collection. Cash flow from financing activities reached **VND 130 billion**, supported by bank funding. The Company's cash flow statement is presented in the following table:

Unit: Million VND

Cash flow	2020	2021	2022	2023	2024
Operating activities	(716)	14,999	25,500	50,250	60,755
Investment activities	(27,049)	(23,441)	(126,696)	(75,782)	(205,384)
Financing activities	22,237	17,752	85,889	45,234	129,988
Total	(5,527)	9,310	(15,307)	19,702	(14,641)

7. Plan for 2025

- Maintain a revenue growth rate of 10% or more, aiming to reach VND 1,000 billion within the next 3 years.

Target (Billion VND)	Actual 2024	Plan for 2025	Growth rate (%)
Revenue	793.3	868	9.4%
Profit before tax	60.5	68	12.4%

- Expand into new markets while strengthening current market.
- Continue implementing projects: Expansion of the Herbal Medicine Factory, Liquid Medicine Factory, Food Factory, Canteen and Parking Lot to meet coverage requirements at Binh Hoa Industrial Park.
- Exploiting the capacity of completed factories.
- Tighten cash flow management.
- Develop human resources, enhance professional skills and leadership capabilities, encourage innovation, optimize work processes and increase productivity.

8. Conclusion - "Keep Faith"

The outstanding achievements of 2024 and previous years reflect the sustainable development of Agimexpharm. We are fully confident in our direction and development plans thanks to:

- 1) An experienced and passionate workforce leading a dynamic and creative young team to form a high-quality labor force.
- 2) Continuously investing and upgrading machinery and equipment to keep up with advances in science and technology helps enhance productivity, product quality and automation.
- 3) The product list is continuously supplemented and improved to increase competitiveness and expand the market: add lines of Betalactam antibiotics, injections, infusions, and eye drops.
- 4) Shareholders and partners always stand by Agimexpharm and share long-term benefits together.

These factors form the foundation of Agimexpharm today and its growth potential in the future. On behalf of all Agimexpharm's Shareholders, Partners, Government Agencies, and Employees, we express our sincere gratitude and strive to bring worthy value while maintaining sustainable growth.

Sincerely thank you and best regards!

AGIMEXPHARM PHARMACEUTICAL JSC
GENERAL DIRECTOR

PHAR. NGUYEN VAN KHA

An Giang, February 14, 2025



DRAFT

**AUDITED FINANCIAL STATEMENTS
YEAR 2024**

To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC.

The 2024 audited financial statements of Agimexpharm Pharmaceutical Joint Stock Company have been audited by A&C Auditing and Consulting Co., Ltd. and disclosed in accordance with regulations and published on the company's website, including:

1. Statement of the Board of Directors
2. Independent auditor's report
3. Balance sheet
4. Income statement
5. Cash flow statement
6. Notes to the financial statements

Among them, some key figures from the 2024 audited financial statements are as follows:

Unit: Vietnamese Dong (VND)

STT	Key indicators	2024	2023
1	Total assets	1,094,278,885,505	897,763,414,064
2	Gross revenue	799,149,067,144	728,406,444,724
3	Net revenue	793,261,193,442	725,130,106,273
4	Profit before tax	60,481,183,498	54,195,754,105
5	Profit after tax	48,889,738,710	43,612,786,683

Respectfully submitting to the General Meeting of Shareholders for consideration and approval.

Sincerely!

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**

PHAR. PHAM THI BICH THUY

No.: .../TT-AGP.DHDCD

An Giang, February 14, 2025



DRAFT

PROPOSAL
SELECTION OF AN AUDIT FIRM
FOR THE 2025 FINANCIAL STATEMENTS

To: The 2025 Annual General Meeting of Shareholders

- Pursuant to the Enterprises Law No. 59/2020/QH14 on June 17, 2020, effective from January 1, 2021.
- Pursuant to the Charter of Organization and Operation of Agimexpharm Pharmaceutical Joint Stock Company.
- Pursuant to the Company's actual circumstances.

The Board of Supervisors proposes that the General Meeting of Shareholders authorizes the Board of Directors to select one (1) of the following five (5) Audit Firms for the 2025 financial statements:

- Deloitte Vietnam Co., Ltd.
- AASC Auditing Firm Co., Ltd.
- A&C Auditing and Consulting Co., Ltd.
- DFK Vietnam Auditing Co., Ltd.
- Sao Viet Auditing Co., Ltd.

Selection criteria:

- The audit firm must be approved by the State Securities Commission as eligible to conduct audits in 2025.
- The audit firm must be reputable and experienced.
- The service fee must be reasonable.


We respectfully submit this proposal to the General Meeting of Shareholders for approval and authorize the Board of Directors to select an audit firm for the 2025 financial statements audit.

We look forward to the approval of the Esteemed Shareholders.

Sincerely.

ON BEHALF OF THE BOARD OF SUPERVISORS
HEAD OF THE BOARD

MBA. TRAN THI THANH HANG



PROPOSAL

FOR THE 2024 PROFIT DISTRIBUTION AND DIVIDEND PAYOUT

(For the fiscal year ending 31 December, 2024)

To: The 2025 Annual General Meeting of Shareholders

Pursuant to the business performance results of 2024 and the 2024 Audited Financial Statements dated February 12, 2025, the Board of Directors proposes the profit distribution and dividend payout for 2024 as follows:

Unit: VND (Vietnamese Dong)

Items	Percentage	Amount	Notes
Profit before tax		60,481,183,498	
Corporate income tax		11,591,444,788	
Retained earnings		48,889,738,710	
1/ Appropriation for bonus fund for the Board of Directors and the Board of Supervisors	1.49%	728,871,010	
2/ Appropriation for Bonus and Welfare Fund	7.50%	3,667,008,458	
3/ Dividend payout:	71.01%	34,715,911,500	15% of charter capital
3.1 In form of cash (5%)	23.67%	11,571,970,500	5% of charter capital
3.2 In form of shares (10%) (Details in the Proposal on Plan for issuing shares to pay dividends)	47.34%	23,143,941,000	10% of charter capital
4/ Remaining profit appropriate for Development and Investment Fund	20.00%	9,777,947,742	

Notes:

1/ Appropriation for the 2024 bonus fund for the Board of Directors and the Board of Supervisors as follows:

Total bonus fund for the Board of Directors: VND 728,871,010

Bonus for meeting the profit before tax plan (1% of profit before tax): VND 604,811,835

Bonus for exceeding the profit before tax plan (5% of excess profit): VND 124,059,175


2/ Bonus and Welfare Fund: Used for rewards, employee welfare, and other social welfare activities.

3/ Investment and development fund: Used for expanding business operations, purchasing fixed assets (land, machinery, equipment, transportation, vehicles), scientific research, product development research, training, offsetting tax settlement differences, and losses in assets and debts. The Board of Directors authorizes the Board of Management to review the use of this fund within the limits as prescribed by law or the company's charter.

Sincerely.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN

PHAR. PHAM THI BICH THUY



No. /TT-AGP.DHDCD

DRAFT

An Giang, February 14, 2025

PROPOSAL

SALARY AND BONUS FOR THE BOARD OF DIRECTORS AND THE BOARD OF SUPERVISORS

To: The 2025 Annual General Meeting of Shareholders

- Pursuant to the Enterprises Law No. 59/2020/QH14 on June 17, 2020, effective from January 1, 2021.
- Pursuant to the Charter of Organization and Operation of Agimexpharm Pharmaceutical Joint Stock Company.
- Pursuant to the Company's actual circumstances.

The Board of Directors respectfully submits to the 2025 General Meeting of Shareholders for approval:

1. Salary and bonus for the Board of Directors and the Board of Supervisors in 2024:

- | | |
|--|-----------------|
| - Salary paid in 2024: | VND 700,000,000 |
| - Bonus balance at the beginning of 2024: | VND 29,823,100 |
| - Bonus allocated from 2023 profit: | VND 551,745,246 |
| - Bonus paid in 2024: | VND 579,000,000 |
| - Remaining bonus carried forward to 2025: | VND 2,568,346 |

2. Salary and bonus plan for the Board of Directors and the Board of Supervisors in 2025:

- | | |
|---|---------------------------|
| - Fixed salary: | VND 700,000,000 per year |
| - Bonus for 2025 includes: | |
| + Meeting the profit before tax plan: | 1% of profit before tax |
| + Exceeding the profit before tax plan: | 5% of excess profit |
| + Bonus for the General Director for meeting the profit plan: | 0.5% of profit before tax |

We look forward to the approval of the Esteemed Shareholders.

Sincerely.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**

PHAR. PHAM THI BICH THUY

No. TT-AGP.DHDCD

An Giang, February 14, 2025



DRAFT

PROPOSAL

Re: Plan for issuing shares to pay 2024 dividends

To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC

- Pursuant to the Enterprises Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Securities Law No. 54/2019/QH14 dated on November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP of the Government dated December 31, 2020, detailing the implementation of certain provisions of the Securities Law;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company (“the Company”).

The Board of Directors (“BoDs”) of Agimexpharm Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders (“GMS”) to approve a plan for issuing shares to pay 2024 dividend with the following contents:

- 1. Name of share:** Shares of Agimexpharm Pharmaceutical Joint Stock Company
- 2. Share type:** Common shares
- 3. Par value:** VND 10,000/share
- 4. Current charter capital:** VND 231,439,410,000
- 5. Total number of issued shares:** 23,143,941 shares
Of which:
 - Total number of outstanding shares: 23,143,941 shares
 - Total number of treasury shares: 0 shares
- 6. Estimated number of shares to be issued:** 2,314,394 shares
- 7. Total value of issuance at par value:** VND 23,143,940,000
- 8. Eligible subscriber:** Existing shareholders whose names appear on the final shareholder list as of the record date. The record date for the shareholder list will be determined by the BoDs, as authorized by the GMS.
- 9. Issuance ratio** (estimated number of shares to be issued/number of outstanding shares): 10%
- 10. Subscription ratio:** 10:01. For every 1 share owned, a shareholder will receive 1 right to subscribe for additional shares. Every 10 rights will entitle the shareholder to 1 additional new share.
- 11. Source of capital:** Retained earnings after tax as of December 31, 2024, based on the audited financial statements for the year 2024 of Agimexpharm Pharmaceutical Joint Stock Company.
- 12. Issuance method:** The shares issued to existing shareholders will be distributed through the exercise of subscription rights.
- 13. The plan to handle the fractional shares:** The number of additional shares issued to each shareholder will be rounded down to the nearest whole number, and any fractional shares (if any) will be canceled.

*For example: Shareholder A owns 128 shares as of the record date. With a subscription ratio of 10:1, Shareholder A is entitled to receive $(128/10 * 1) = 12.80$ new shares. Following this calculation method, Shareholder A will receive 12 additional shares, and the fractional portion of 0.80 shares will be canceled.*

The difference between the total projected amount for issuing shares to pay dividends (calculated at a par value of VND 10,000 per share) and the total value of shares actually distributed to existing shareholders (calculated at a par value of VND 10,000 per share) will be allocated to the Company's Development Investment Fund.

14. Expected time of issuance: After the State Securities Commission (SSC) acknowledges receipt of the complete issuance report from the Company, the issuance is expected to take place in the second to fourth quarter of 2025. The GMS authorizes the BoDs to determine the appropriate issuance time to ensure shareholders' interests and compliance with legal regulations.

15. Additional securities registration and additional trading registration: The GMS approves and authorizes the BoDs to carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange.

16. Approval of charter capital amendment: Approve the amendment of the Company's Charter (regarding charter capital) and the adjustment of the Enterprise Registration Certificate with the Department of Planning and Investment of An Giang Province, following the written notification from the SSC confirming receipt of the issuance result report.

17. Authorization to the BoDs:

The GMS authorizes the Company's BoDs to carry out the following tasks related to the issuance:

- Make, amend, supplement, and finalize the content of the above-mentioned share issuance plan, and adjust the issuance plan along with other related documents as necessary, based on the actual situation of the Company, or as required by the SSC and other competent authorities, or to ensure compliance with relevant legal regulations (if any);
- Select the shareholder record date to implement the aforementioned share issuance plan;
- Make amendments and supplements to the relevant provisions in the Company's Charter to reflect the increased charter capital after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch, and additional trading registration with the Hanoi Stock Exchange for the number of additional shares issued, based on the actual results of the issuance, after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for amending the Company's business registration to reflect the change in charter capital based on the actual results of the issuance with competent authorities after the SSC provides written notification of the receipt of the issuance result report;
- Depending on specific circumstances, the BoDs may authorize the General Director to carry out one or several specific tasks mentioned above;
- Make decisions on any other issues arising related to the issuance of shares for dividend payment.

Respectfully submitted to the GMS for consideration and approval.

Sincerely thank you.

Recipients:

- Shareholders of the Company;
- Board of Directors;
- Archived: Secretary of the BoDs

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**

PHAR. PHAM THI BICH THUY



No. .../TT-AGP.DHDCD

DRAFT

An Giang, February 14, 2025

PROPOSAL

Re: Plan for issuing shares under the Employee Stock Ownership Program (ESOP)

To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC

- Pursuant to the Enterprises Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Securities Law No. 54/2019/QH14 dated on November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP of the Government dated December 31, 2020, detailing the implementation of certain provisions of the Securities Law;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company ("the Company").

To implement the compensation policy, to encourage employees who have contributed to the development of the Company, and to supplement the Company's working capital, the Board of Directors ("BoDs") of Agimexpharm Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders ("GMS") for approval the share issuance plan under the Employee Stock Ownership Program ("ESOP") with the following details:

1. **Name of share:** Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. **Share type:** Common shares
3. **Securities code:** AGP
4. **Par value:** VND 10,000/share
5. **Current charter capital:** VND 231,439,410,000
6. **Total number of issued shares:** 23,143,941 shares
Of which:
 - Total number of outstanding shares: 23,143,941 shares
 - Total number of treasury shares: 0 shares
7. **Maximum number of shares expected to be issued:** 1,157,197 shares
8. **Maximum total value of issuance at par value:** VND 11,571,970,000
9. **Purpose of issuance:** To issue shares under the ESOP.
10. **Eligible subscriber:** Employees who have contributed to the development of Agimexpharm Pharmaceutical Joint Stock Company. The GMS authorizes the BoDs to approve the criteria, the list of employees eligible to participate in the program and the specific number of shares each employee is entitled to purchase.
11. **Issuance ratio (estimated number of shares to be issued/number of outstanding shares):**
5%



12. **Issuance price:** VND 18,000 per share
13. **Expected total funds to be raised:** VND 20,829,546,000
14. **Principles for determining the number of shares allocated to each employee:** The GMS authorizes the BoDs to decide the principles for determining the number of shares to be allocated to each employee at the time of issuance.
15. **Transfer restrictions:** Shares issued under the ESOP will be subject to a transfer restriction for 01 year from the end of the issuance period.
16. **Plan for handling when employees resign during the transfer restriction period:** The GMS has decided not to revoke the shares if employees resign during the transfer restriction period.
17. **Expected time of issuance:** After being approved by the GMS and the State Securities Commission (SSC) acknowledges receipt of the complete issuance report from the Company, the issuance is expected to take place in the second to fourth quarter of 2025. The GMS authorizes the BoDs to determine the appropriate issuance time to ensure shareholders' interests and compliance with legal regulations.
18. **Plan for using funds from the issuance:** The entire amount raised from the issuance will be used to supplement the working capital for the Company's business operations.
19. **Plan for handling unsubscribed shares:** The number of unsubscribed shares will be distributed to other eligible employees as authorized by the GMS in accordance with the program's purpose, provided that the offering price is not lower than VND 18,000 per share. In the event that the BoDs is unable to find suitable employees, the GMS authorizes the Board to adjust the total number of shares to be issued to reflect the actual number of shares distributed.
20. **Additional securities registration and additional trading registration:** The GMS approves and authorizes the BoDs to carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange.
21. **Approval of charter capital amendment:** Approve the amendment of the Company's Charter (regarding charter capital) and the adjustment of the Enterprise Registration Certificate with the Department of Planning and Investment of An Giang Province, following the written notification from the SSC confirming receipt of the issuance result report.

22. Authorization to the BoDs:

The GMS authorizes the Company's BoDs to carry out the following tasks related to the issuance:

- Make, amend, supplement, and finalize the content of the above-mentioned share issuance plan, and adjust the issuance plan along with other related documents as necessary, based on the actual situation of the Company, or as required by the SSC and other competent authorities, or to ensure compliance with relevant legal regulations (if any);
- Approve the plan to ensure that the share issuance complies with regulations on foreign ownership ratios in the event that shares are issued to foreign investors under the ESOP;
- Make a detailed working capital utilization plan;
- Decide the issuance timeline after the SSC confirms receipt of the complete issuance report from the Company;
- Approve the criteria and list of employees eligible to participate in the program, the principles for determining the number of shares allocated to each individual, and the implementation timeline;

- Decide on the handling of unsubscribed shares (if any);
- Make amendments and supplements to the relevant provisions in the Company's Charter to reflect the increased charter capital after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange for the number of additional shares issued under the plan approved by the GMS, after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for amending the Company’s business registration to reflect the change in charter capital based on the actual results of the issuance with competent authorities after the SSC provides written notification of the receipt of the issuance result report;
- Depending on specific circumstances, the BoDs may authorize the General Director to carry out one or several specific tasks mentioned above;
- Make decisions on any other issues arising related to the issuance of shares under ESOP.

Respectfully submitted to the GMS for consideration and approval.

Sincerely thank you.

Recipients:

- Shareholders of the Company;
- Board of Directors;
- Archived: Secretary of the BoDs .

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**

PHAR. PHAM THI BICH THUY





No. .../TT-AGP.DHDCD

DRAFT

An Giang, February 14, 2025

PROPOSAL

**Regarding the Amendment of the Charter
of Agimexpharm Pharmaceutical Joint Stock Company**

- Pursuant to the Enterprises Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Securities Law No. 54/2019/QH14 dated on November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP of the Government dated December 31, 2020, detailing the implementation of certain provisions of the Securities Law;
- Pursuant to Circular No. 116/2020/TT-BTC of the Minister of Finance dated December 31, 2020, providing guidance on corporate governance regulations applicable to public companies;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company;
- Pursuant to current regulations and the practical needs of Agimexpharm Pharmaceutical Joint Stock Company.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the amendments to the Charter on organization and operation of Agimexpharm Pharmaceutical Joint Stock Company as follows:

Charter (May 2024)	Amended content 2025	Notes
Introduction	Introduction	
This Charter was approved by the 2024 Annual General Meeting of Shareholders on March 15, 2024, and was amended and supplemented according to the Board of Directors' Resolution No. 06/NQ-AGP.HDQT dated May 20, 2024. The company is organized and operates in accordance with this Charter, the Law on Enterprises, and other relevant current legal regulations.	This Charter was approved by the 2025 Annual General Meeting of Shareholders on March 8, 2025, and was amended and supplemented according to the Board of Directors' Resolution No. .../NQ-AGP.HDQT dated, 2025. The company is organized and operates in accordance with this Charter, the Law on Enterprises, and other relevant current legal regulations.	Amended in accordance with the approval at the 2025 Annual General Meeting of Shareholders and any Board of Directors' Resolutions (if any).
Article 5. Charter capital, shares and founding shareholders	Article 5. Charter capital, shares and founding shareholders	
1. The Company's charter capital is VND 231,439,410,000 (two hundred thirty-one billion, four hundred thirty-nine million, four hundred ten thousand Vietnamese dong).	1. The Company's charter capital is VND (.....). The total charter capital is divided into shares, with a par value of VND 10,000 per share .	Amended based on the actual results of the issuance of shares for dividend payment and the issuance of shares under the

Charter (May 2024)	Amended content 2025	Notes
The total charter capital is divided into 23,143,941 shares , with a par value of VND 10,000 per share .		employee stock option program (ESOP)
Article 53. Effective date	Article 53. Effective date	
1. This Charter, consisting of 21 chapters with 53 articles, was approved by the 2024 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint Stock Company on March 15, 2024 in An Giang and amended and supplemented on May 20, 2024, as per the Resolution No. 06/NQ-AGP.HĐQT of the Board of Directors. The full text of this Charter takes effect as of May 20, 2024.	1. This Charter, consisting of 21 chapters with 53 articles, was approved by the 2025 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint Stock Company on March 08, 2025 in An Giang and amended and supplemented on, 2025, as per the Resolution No. .../NQ-AGP.HĐQT of the Board of Directors. The full text of this Charter takes effect as of, 2025.	Amended in accordance with the approval at the 2025 Annual General Meeting of Shareholders and any Board of Directors' Resolutions (if any).

The General Meeting of Shareholders authorizes the Board of Directors to amend the Company's Charter and carry out the necessary procedures in accordance with applicable laws.

Sincerely.

Recipients:

- Shareholders of the Company;
- Board of Directors, Board of Supervisors, Board of Management
- Archived: Secretary of the BoDs

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**

PHAR. PHAM THI BICH THUY

DRAFT

An Giang, March 8, 2025



RESOLUTION

The 2025 Annual General Meeting of Shareholders

GENERAL MEETING OF SHAREHOLDERS

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to the Enterprises Law No. 59/2020/QH14 on June 17, 2020, effective from January 1, 2021;

Pursuant to the Charter of Organization and Operation of Agimexpharm Pharmaceutical Joint Stock Company;

Pursuant to the voting results on matters approved at the 2025 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint Stock Company, held at Hoa Binh 1 Restaurant on March 8, 2025.

RESOLVED:

Article 1. Approval of the 2024 Board of Directors' activity report and assessment - Plans and targets for 2025; *Voting rate:%*.

Article 2. Approval of the 2024 Board of Management's business operations report and plans for 2025; *Voting rate:%*.

Article 3. Approval of the 2024 Audited Financial Statements; *Voting rate:%*.

Article 4. Approval of the 2024 Board of Supervisors' report; *Voting rate:%*.

Article 5. Approval of the proposals presented by the Board of Directors:

- 1) Proposal for selecting an auditing firm for the 2025 financial statements; *Voting rate:%*.
- 2) Proposal for the 2024 profit distribution and dividend payout; *Voting rate:%*.
- 3) Proposal for salary and bonus for the Board of Directors and the Board of Supervisors; *Voting rate:%*.
- 4) Proposal on the plan for issuing shares to pay 2024 dividends; *Voting rate:%*.
- 5) Proposal on the plan for issuing shares under the Employee Stock Ownership Program (ESOP); *Voting rate:%*.
- 6) Proposal on amendments to the Company's Charter; *Voting rate:%*.

Article 6. This resolution has been approved with a voting rate of% and shall take effect from the date of conclusion of the General Meeting. All shareholders of Agimexpharm Pharmaceutical Joint Stock Company, members of the Board of Directors, members of the Board of Supervisors, and all employees of the company are responsible for implementing this resolution. At the same time, the General Meeting of Shareholders authorizes the Board of Directors to detail this resolution into plans and tasks for directing and organizing its implementation.

Recipients:

- The Company's shareholders;
- The State Securities Commission;
- The Stock Exchange;
- Board of Directors;
- Board of Supervisors;
- Archived: Secretary of the BoDs.

**ON BEHALF OF THE PRESIDIUM
CHAIRWOMAN OF THE BODS**

PHAR. PHAM THI BICH THUY